Terns Pharmaceuticals, Inc. Free Cash Flow

Free Cash Flow of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow growth rates and interactive chart. Free cash flowis calculated as operating cash flow minus of capital expenditures. Interest payments are excluded from the generally accepted definition of free cash flow. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. Some investors prefer FCF or FCF per share over earnings and earnings per share as a measure of profitability. However, because FCF accounts for investments in property, plant, and equipment it can be lumpy over time. Free cash flow is usually used in discounted cash flow models to determine a company's intrinsic value.


Highlights and Quick Summary

  • Free Cash Flow for the quarter ending March 31, 2022 was $-13.5 Million (a -0.35% decrease compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow increased by 53.85%
  • Annual Free Cash Flow for 2021 was $-44.9 Million (a 43.64% increase from previous year)
  • Annual Free Cash Flow for 2020 was $-31.3 Million (a -53.46% decrease from previous year)
  • Annual Free Cash Flow for 2019 was $-67.1 Million (a 271.56% increase from previous year)
  • Twelve month Free Cash Flow ending March 31, 2022 was $-44.1 Million (a -1.78% decrease compared to previous quarter)
  • Twelve month trailing Free Cash Flow increased by 19.5% year-over-year
Trailing Free Cash Flow for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-44.1 Million $-44.9 Million $-38.7 Million $-36.9 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow of Terns Pharmaceuticals, Inc.

Most recent Free Cash Flowof TERN including historical data for past 10 years.

Interactive Chart of Free Cash Flow of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Free Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-13.54
2021 $-13.59 $-8.16 $-8.8 $-14.34 $-44.89
2020 $-7.43 $-6.32 $-8.92 $-7.72 $-31.25
2019 $-67.12 $-67.14
2018 $-18.07

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.